Group | Disease and Intervention Dynamics

The research group Disease and Intervention Dynamics focuses on developing and using mathematical models to understand parasite, host and intervention dynamics. The main aim is to generate evidence for decision-making along the whole pathway of new tool development, from preclinical to clinical testing, and at implementation in real populations and health systems. The model-based evidences ensure efficient selection of optimal drugs and vaccines to achieve disease burden reduction and elimination.

Our Main Emphasis

In particular, we investigate pharmacokinetic and pharmacodynamics at pre-clinical and clinical level for new drugs to treat malaria and helminths. We collaborate with the University Hospital Basel on understanding drug-drug interactions for HIV drugs.  We assess new malaria vaccines at clinical and implementation level. And we use data and models to explore most effective, cost-effective and equitable delivery of current and new malaria interventions.

Melissa Penny

Melissa Penny, SNF Professor, PhD, PD

Lee T.E, Penny M.A. Identifying key factors of the transmission dynamics of drug-resistant malaria. J Theor Biol. 2019;462:210-220. DOI: 10.1016/j.jtbi.2018.10.050

Meister I et al. Pooled population pharmacokinetic analysis of tribendimidine for the treatment of Opisthorchis viverrini infections. Antimicrob Agents Chemother. 2019;63(4):e01391-18. DOI: 10.1128/AAC.01391-18

Stader F, Penny M.A, Siccardi M, Marzolini C. A comprehensive framework for physiologically based pharmacokinetic modelling in MatlabĀ®. CPT Pharmacometrics Syst Pharmacol. 2019(in press). DOI: 10.1002/psp4.12399

Stader F, Siccardi M, Battegay M, Kinvig H, Penny M.A, Marzolini C. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes. Clin Pharmacokinet. 2019;58(4):483-501. DOI: 10.1007/s40262-018-0709-7

Ali A.M et al. Population pharmacokinetics of the antimalarial amodiaquine: a pooled analysis to optimize dosing. Antimicrob Agents Chemother. 2018;62(10):e02193-17. DOI: 10.1128/AAC.02193-17